CAH vs HKPD
Cardinal Health Inc. and Cellyan Biotechnology Co. Ltd., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CAH | HKPD |
|---|---|---|
| Revenue | $254.2B | $20.3M |
| Net income | $1.7B | $-27,056 |
| Gross margin | 3.8% | 11.9% |
| Net margin | 0.7% | −0.1% |
| Return on equity | · | −0.6% |
| Diluted EPS | $7.23 | −$0.00 |
| Dividend / share | $2.04 | · |
| Payout ratio | 28.6% | · |
| Free cash flow | $4.5B | $499,298 |
| Equity | $-2.9B | $5.0M |
| Net debt / equity | · | 0.23× |
| Current ratio | 0.88× | 2.99× |
| Revenue CAGR 5y | 9.4% | · |
| Profit CAGR 5y | 22.9% | · |
CAH bills 12516.0× the revenue of HKPD, and HKPD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | CAH | HKPD |
|---|---|---|
| FY2024 | $222.6B | $20.3M |
| FY2023 | $226.8B | $16.7M |
| FY2022 | $205.0B | $12.6M |
Bottom line
| Fiscal year | CAH | HKPD |
|---|---|---|
| FY2024 | $1.6B | $-27,056 |
| FY2023 | $852.0M | $1.3M |
| FY2022 | $330.0M | $998,196 |
Standard deviation, each side
HKPD's net margin has been more volatile than CAH's over the 3 comparable fiscal years — 3.8 percentage points of standard deviation against 0.2.
3 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between CAH and HKPD over these 3 fiscal years — CAH led in 1 and HKPD in 2.
3 of 19 comparable fiscal years — a year missing data on either side is not counted.